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Morbidity outcomes by ESRD treatment modality. Practice to say that there is no clear, definitive evidence for a
patterns in both peritoneal dialysis and hemodialysis have clinically large difference in survival, at least at this stage.
changed dramatically in recent years. Most recent clinical stud- The practice of both peritoneal dialysis and hemodialysisies comparing peritoneal dialysis and hemodialysis have used
is evolving rapidly. It is quite likely that improvementsmortality as outcome. Surprisingly few studies have compared
in the practice of both modalities will continue to occur.hospitalization or other measures of morbidity. Several meth-
odological issues cloud comparisons, including non-constant It is also quite possible that improvement may be greater
hazards ratios, a much higher rate of transfer from peritoneal in one modality. It is imperative that the nephrology
dialysis to hemodialysis than vice versa, and the very real possi- community continuously checks that differences in mor-bility of differences in ascertainment of morbidity data, such
tality remain acceptably low. This is the essence of clini-as hospitalization. We examined a prospective, multicenter
cal governance. It may seem somewhat boring and pre-cohort of 822 consecutive patients starting dialysis therapy.
Comorbidity assessment was extensive. Adjusted mortality es- dictable to suggest that survival is the same in both
timates were similar in hemodialysis and peritoneal dialysis modalities now, as it was last year and the year before.
patients. Conclusions about hospitalization rates were heavily
Of course, the only way to know that we are not provid-dependent on 2 factors: whether comparisons began at incep-
ing our patients with a relatively substandard therapy istion of dialysis therapy or at 3 months, and whether intention-
to-treat or treatment-received analysis was used. Taken to- to actually check.
gether, when early treatment switches were accounted for, Remarkably few studies have compared the relative
peritoneal dialysis was associated with higher hospitalization morbidity of hemodialysis and peritoneal dialysis. The
rates. We also examined the reason for hospitalization. A dif-
logistical barriers to carrying out an easily-generalizable,ferential hospitalization pattern was observed, with peritoneal
randomized, controlled trial are considerable. For exam-dialysis patients showing higher rates for vascular admissions
and admissions related to dialysis technique, and lower rates ple peritoneal dialysis is often chosen because it can be
of non-technique-related infections. Comparison of morbidity performed at home. The Veterans Administration Trial,
is an important, understudied, aspect of hemodialysis/perito- published in 1984, was a very compelling description
neal dialysis comparisons. Methodological issues can have a
of the difficulties in doing a trial like this [4]. In thislarge impact on morbidity comparisons. Potentially large mor-
multicenter trial, patients were randomly assigned to usebidity differences may exist without apparent differences in
mortality. intermittent peritoneal dialysis or home hemodialysis.
Patient enrollment was clearly difficult, as only 114 of
398 (29%) patients screened were actually randomized
Hemodialysis and peritoneal dialysis are clearly very to home hemodialysis or intermittent peritoneal dialysis.
different modes of dialysis therapy. There is an aston- During the study, 49% switched from peritoneal dialysis
ishing variation in the relative proportion of patients to hemodialysis, compared to 9.1% in the opposite direc-
treated by each modality in different countries. The rela- tion [4]. It is conventional in clinical trials to use inten-
tive contribution of socioeconomic and medical opinion tion-to-treat analysis, attributing outcome to initial treat-
to this disparity is not well worked out. ment assignment, irrespective of whether a patient
In recent years, clinical outcome studies comparing actually gets the assigned treatment, the comparator,
hemodialysis and peritoneal dialysis have focused almost neither, or both. Obviously, if most patients in a compar-
exclusively on mortality. Some studies have suggested ative trial actually end up on one of the treatments being
that peritoneal dialysis may be associated with better compared, it is going to be exceedingly difficult to show
survival [1], some have suggested the opposite [2], while a difference between treatments using intention-to-treat
others have shown no difference [3]. It seems reasonable analysis. The Veteran’s Administration Trial was a good
demonstration of this truism.
Observational studies must be used in the absence of
large clinical trials. Some of the desirable characteristics 2000 by the International Society of Nephrology
S-82
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Table 1. Cardinal features of observational studies of chronic renal failure, typified by studies with a cross-
that increase validity
sectional start. Another issue that has yet to be addressed
Are the comparison groups well-defined? is whether data ascertainment is similar for hemodialysis
Are the comparison groups representative? and peritoneal dialysis patients. It is likely that mostIs there a complete description of important determinants of
hospital admissions for hemodialysis patients are to theoutcome, other than the primary comparison?
Do patients in both comparison groups start at a similar point in primary center at which dialysis began; this may not be
the course of the disease? the case for non-dialysis–related admissions of perito-Were exposures measured in the same way in the groups being
neal dialysis patients, at least in our dialysis services.compared?
Were outcomes measured in the same way in the groups being Future prospective morbidity studies will need to have
compared? mechanisms in place to minimize this problem.Was follow-up sufficiently long?
The fact that a switch from peritoneal dialysis to hemo-Was follow-up complete?
dialysis is much more common than vice versa also com-
plicates outcome comparisons. Intention-to-treat analy-
sis is a true, valid, prospective approach to comparison,
Table 2. Factors complicating morbidity comparisons of because it uses no information collected between assess-
hemodialysis and peritoneal dialysis
ment of exposure (hemodialysis or peritoneal dialysis
Unmeasured comorbidity. at the start of the analytic time-frame) and outcome.
Risks may vary over time. Treatment-received analysis, used in many recent stud-Very high likelihood of switch between therapies.
ies, assigns outcome to the therapy in use at the time ofLower likelihood of switch from hemodialysis to peritoneal
dialysis than vice versa. the outcome. This type of analysis accounts nicely for
Hemodialysis patients are more captive than peritoneal dialysis the possibility of multiple switches. However, to a purist,patients with the possibility that ease and threshold for
it can never be considered truly prospective, because itascertainment of morbid events may not be equal.
uses information collected between exposure and out-
come assessment. In our opinion, because switch behav-
ior is so imbalanced, both intention-to-treat and treat-
ment-received analyses are needed to get a real idea ofof an observational study are shown in Table 1. Very
large patient and event numbers are desirable because comparative outcome.
To our knowledge, there have been no large-scale,risk estimates can be made with precision, and because
a reasonable attempt at outcome comparisons in major prospective, inception cohort studies comparing morbid-
ity in hemodialysis and peritoneal dialysis patients in thissubgroups can be made. Large patient and event num-
bers, however, can never make up for the absence of decade. Our group has compared morbidity in 2 very
different prospective studies of patients beginning end-any of the 8 characteristics shown in Table 1. Only a
planned approach can guarantee these features. Prospec- stage renal disease therapy. The first was a study of the
1980s that focused primarily on cardiac disease in dialysistive studies starting from a single, well-defined point—of
which inception of dialysis therapy is the most obvious— patients. Baseline and annual assessments of clinical and
echocardiographic disease were made in 433 dialysis pa-represent the most feasible way of achieving these objec-
tives. tients. The incidence rates of new ischemic heart disease
and cardiac failure were similar in both groups, as wasTable 2 illustrates some of the difficulties that com-
plicate hemodialysis/peritoneal dialysis outcome com- the evolution of cardiomyopathy on echocardiography
[5]. This study is difficult to generalize to current practice,parisons. The problem of differences in unmeasured
comorbidity cannot be resolved outside the setting of a primarily because it reflects clinical practice in vogue a
decade ago, and because it involved patients in only 2randomized trial. People with acute problems precipitat-
ing end-stage renal disease are much more likely to re- geographic areas, Montreal and St John’s, both in East-
ern Canada.ceive hemodialysis as initial therapy. Few studies have
validated, quantitative indices of total comorbidity. In We are currently examining data from a prospective,
multicenter cohort of 822 consecutive patients startingtheir absence, there is a strong possibility that compari-
son studies that start at inception of dialysis therapy may dialysis therapy. This study involved 11 University cen-
ters across Canada and was assembled over a relativelybe set up to favor peritoneal dialysis. Many studies start
observation at 3 months. It is not clear, however, whether short period of time. Comorbidity assessment was exten-
sive because a primary objective of the study was tothis first-treatment effect has dissipated by 3 months.
Several studies have shown that adjusted mortality determine whether aggregate comorbidity scores starting
dialysis therapy accurately predicted mortality [6]. Peri-rates of hemodialysis and peritoneal dialysis do not re-
main constant over time [1, 2, 5]. Non-constant hazard toneal dialysis was used by 34% of patients at initiation
of dialysis, compared to 50% at 3 months. Adjustedratios necessarily complicate the interpretation of studies
that do not begin at a uniform time-point in the course mortality estimates were similar in hemodialysis and
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peritoneal dialysis patients. The overall hospitalization rates of non-technique-related infections (the authors,
pers. comm.).rate was 40 per 1000 patient-days. Using intention-to-
In conclusion, morbidity is a grossly understudied as-treat analysis based on mode of therapy at initiation of
pect of hemodialysis/peritoneal dialysis comparisons.dialysis therapy, peritoneal dialysis was associated with a
Methodological issues can have a large impact on mor-15% lower (P , 0.001) case-mix-adjusted hospitalization
bidity comparisons. Much prospective research is neededrate. In contrast, when 3 months was chosen as the ana-
to sort out these issues. Methodological consensus (onlytic starting point, peritoneal dialysis was associated
such basic factors as covariates assessed, when to startwith a 31% higher (P , 0.001) hospitalization rate. Using
the analytic clock, whether intention-to-treat, treatment-
a treatment-received approach, peritoneal dialysis was received analysis, or both should be employed, and other
associated with a 10% higher (P , 0.001) hospitalization issues) is needed to allow comparison of studies in place
rate when initiation of dialysis was chosen as the starting and time. Potentially large morbidity differences may
point, and a 26% higher (P , 0.001) hospitalization rate exist without apparent differences in mortality. Morbid-
when 3 months was chosen. Thus, conclusions regarding ity and mortality should be considered in outcome stud-
overall relative hospitalization rates were heavily depen- ies, prognostic decisions and policy decisions.
dent on two factors: whether comparisons began at in-
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used. Overall, it appeared that when early treatment
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